Skip to main
ALLR
ALLR logo

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc is positioned favorably due to its attractive current valuation, with potential significant upside as indicated by a revised net present value (NPV) analysis that sees the value enhanced to $9.25 per share. The company’s drug candidate, stenoparib, has demonstrated promising and durable clinical benefits for patients suffering from advanced recurrent ovarian cancer, addressing a substantial unmet medical need. Finally, the use of proprietary Drug Response Predictor (DRP) technology enhances patient selection, which is expected to improve clinical outcomes and bolster the company’s advancement in the competitive oncology market.

Bears say

Allarity Therapeutics Inc reported a net loss of $2.37 million, equating to an earnings per share (EPS) of $(0.15), which was better than the estimated EPS of $(0.21). Despite the potential upside of the company's innovative therapeutic developments and proprietary Drug Response Predictor technology, substantial risks remain, including liquidity concerns and uncertainties regarding clinical trial outcomes. Additionally, challenges related to regulatory approvals, commercialization, competition, and macroeconomic factors contribute to a negative outlook for the company's stock performance.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.